Signaturefd LLC Purchases 2,632 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

Signaturefd LLC boosted its position in GSK PLC Sponsored ADR (NYSE:GSK) by 6.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,722 shares of the pharmaceutical company’s stock after purchasing an additional 2,632 shares during the quarter. Signaturefd LLC’s holdings in GSK were worth $1,655,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Olde Wealth Management LLC bought a new position in GSK in the first quarter worth about $36,000. Lee Danner & Bass Inc. bought a new position in GSK in the fourth quarter worth about $39,000. First Pacific Financial acquired a new position in shares of GSK during the first quarter valued at about $45,000. CX Institutional acquired a new position in shares of GSK during the first quarter valued at about $46,000. Finally, Garde Capital Inc. acquired a new position in shares of GSK during the first quarter valued at about $51,000. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

Shares of NYSE:GSK opened at $38.34 on Tuesday. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The company’s 50 day moving average is $38.97 and its 200 day moving average is $37.33. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The company has a market cap of $78.49 billion, a PE ratio of 19.76, a price-to-earnings-growth ratio of 1.54 and a beta of 0.50.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the prior year, the company earned $0.43 EPS. GSK’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were issued a $0.4216 dividend. This represents a $1.69 annualized dividend and a yield of 4.40%. The ex-dividend date was Friday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 88.14%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on GSK shares. Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a report on Monday, April 28th. Berenberg Bank restated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price objective on the stock. Finally, Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.